Pacliwel 30 mg/5 mL Injection – Paclitaxel Product Description

What is Pacliwel 30 mg/5 mL Injection?

Pacliwel 30 mg/5 mL Injection is a prescription oncology medicine containing paclitaxel as its active ingredient. The product shown is a 30 mg/5 mL (6 mg/mL) injection supplied as a single-dose vial and intended for intravenous infusion after appropriate preparation and dilution by qualified healthcare professionals. The manufacturer information identifies Pacliwel as a product of Getwell Oncology.

Paclitaxel belongs to a group of anticancer medicines known as taxanes or microtubule inhibitors. It works by interfering with microtubules, structures that cancer cells require to divide and multiply. By disrupting this process, paclitaxel can prevent cancer cells from progressing through cell division and can contribute to the control of certain cancers.

Paclitaxel injection is used in specialist cancer treatment for certain types of ovarian cancer, breast cancer, and non-small-cell lung cancer. Some formulations and treatment protocols also include other specific indications. The exact use depends on the cancer type, stage, previous treatments, overall health, and the oncologist’s treatment plan.

Because Pacliwel is a cytotoxic chemotherapy medicine, it should only be administered under the supervision of an appropriately qualified oncology team in a suitable medical setting.

Uses of Pacliwel 30 mg/5 mL Injection

Paclitaxel is an established chemotherapy medicine used as part of treatment plans for selected cancers. Depending on the approved indication and treatment protocol, paclitaxel may be used for:

• Certain forms of ovarian cancer
• Certain forms of breast cancer
• Certain cases of non-small-cell lung cancer
• Other oncology indications under specialist medical protocols, depending on the formulation and local approvals

Paclitaxel may be used alone or in combination with other anticancer medicines. For example, conventional paclitaxel injection has established uses in combination chemotherapy for some cancers.

The appropriate treatment plan is determined by an oncologist after considering the patient’s diagnosis, laboratory results, previous treatment, organ function, and overall medical condition.

This medicine should only be administered under the supervision of a qualified healthcare professional.

Benefits of Pacliwel 30 mg/5 mL Injection

Pacliwel provides the anticancer activity of paclitaxel and may form an important part of chemotherapy treatment for appropriate patients.

Potential treatment benefits include:

• Helps slow or control the growth of susceptible cancer cells
• Can form part of combination chemotherapy regimens
• May help reduce or control cancer burden when appropriate
• Can contribute to disease management in selected cancers
• May support an overall oncology treatment strategy designed by a specialist

These benefits should not be interpreted as a guarantee of cure. Cancer treatment outcomes vary considerably between individuals and depend on factors such as cancer type, stage, tumor characteristics, previous therapy, and response to treatment.

How Does Pacliwel Work?

Pacliwel contains paclitaxel, which acts primarily on microtubules inside cells. Microtubules are dynamic structures involved in cell division and several other cellular functions.

Paclitaxel stabilizes microtubules and interferes with their normal reorganization during cell division. Cancer cells generally divide more rapidly than many normal cells, so disrupting this process can interfere with their ability to multiply.

In simple terms, paclitaxel helps prevent susceptible cancer cells from completing normal cell division. This makes it possible for the medicine to contribute to slowing cancer growth or controlling disease as part of an appropriate chemotherapy regimen.

Because paclitaxel can also affect healthy cells that divide rapidly, treatment may produce adverse effects. This is why patients receiving paclitaxel require medical monitoring.

How is Pacliwel Administered?

Pacliwel is an intravenous chemotherapy formulation and is not intended for self-administration. The product information identifies the 30 mg/5 mL presentation as a single-dose vial for intravenous infusion after dilution.

The oncology team determines the appropriate treatment schedule based on the patient’s cancer and clinical circumstances. Healthcare professionals also assess laboratory results and other safety factors before treatment.

Patients should not attempt to calculate, prepare, dilute, or administer paclitaxel themselves. The exact treatment regimen is individualized by the treating oncology team.

Pacliwel Side Effects

Like all medicines, Pacliwel may cause side effects, although not everyone experiences them.

Common or Important Side Effects

Possible adverse effects associated with paclitaxel include:

• Hair loss
• Tiredness or weakness
• Nausea or vomiting
• Diarrhea
• Muscle or joint discomfort
• Changes in blood-cell counts
• Peripheral neuropathy, which may cause tingling or numbness
• Injection-related or infusion-related reactions
• Changes in appetite

Because paclitaxel affects rapidly dividing cells, reductions in blood-cell counts can occur. This may increase the risk of infection, anemia, or bleeding depending on which blood cells are affected.

Serious Side Effects

Paclitaxel can cause potentially serious reactions. Immediate medical attention is important if a patient develops symptoms suggestive of a severe allergic reaction, such as:

• Difficulty breathing
• Sudden swelling of the face, lips, tongue, or throat
• Widespread hives or severe rash
• Severe dizziness or other signs of a significant reaction

Severe hypersensitivity reactions, including anaphylaxis, have been reported with conventional paclitaxel injection.

Other potentially serious complications include severe suppression of blood-cell production, significant nerve problems, and heart-related abnormalities. Patients receiving treatment are therefore monitored by their healthcare team.

If side effects persist or become severe, contact the treating healthcare provider promptly.

Warnings and Precautions

Pacliwel requires careful medical supervision because it is a cytotoxic chemotherapy medicine.

Patients should tell their doctor about any history of:

• Allergy or previous reaction to paclitaxel
• Significant blood-count abnormalities
• Liver problems
• Heart problems
• Peripheral neuropathy
• Previous chemotherapy reactions
• Pregnancy or plans to become pregnant
• Breastfeeding

Paclitaxel injection carries an important warning concerning severe hypersensitivity reactions. Conventional formulations may contain excipients associated with allergic reactions, so the treating team needs to know about relevant allergies.

Pregnancy requires particular caution because anticancer medicines may pose risks to a developing fetus. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss their circumstances with their oncology team before treatment.

Patients should also tell healthcare professionals about all medicines, supplements, and health conditions before receiving treatment.

Drug Interactions

Paclitaxel can interact with other medicines because its metabolism and effects can be influenced by several drugs.

Patients should provide their healthcare professional with a complete list of:

• Prescription medicines
• Over-the-counter medicines
• Vitamins
• Herbal products
• Dietary supplements
• Other cancer medicines

Some medicines can affect enzymes involved in paclitaxel metabolism, potentially changing paclitaxel exposure. Other chemotherapy or supportive medicines may also affect blood counts, liver function, nerves, or other systems.

The oncology team should review the patient’s complete medication history before treatment.

Storage and Handling

Pacliwel is a cytotoxic oncology medicine and requires appropriate pharmaceutical storage and professional handling.

General product-handling principles include:

• Keep the medicine in its original packaging until required by authorized healthcare personnel.
• Protect the product according to the manufacturer’s storage instructions.
• Keep it away from children and unauthorized persons.
• Do not use a vial beyond its expiry date.
• Damaged, improperly stored, or questionable vials should not be used.
• Cytotoxic medicines require appropriate professional procedures for handling and disposal.

The manufacturer’s prescribing information specifically identifies paclitaxel as a cytotoxic anticancer drug and recommends appropriate precautions for handling and disposal.

Frequently Asked Questions

1. What is Pacliwel 30 mg/5 mL used for?

Pacliwel contains paclitaxel, a taxane chemotherapy medicine. Paclitaxel is used in specialist treatment protocols for certain cancers, including selected ovarian, breast, and non-small-cell lung cancers. The exact indication depends on the patient’s diagnosis and the treatment protocol selected by the oncologist.

2. How does Pacliwel work?

Pacliwel contains paclitaxel, which interferes with microtubules required for normal cell division. By disrupting the process of cell division, paclitaxel can inhibit the multiplication of susceptible cancer cells. It is therefore classified as a microtubule inhibitor and taxane chemotherapy medicine.

3. Is Pacliwel safe?

Pacliwel can be an important cancer treatment when appropriately prescribed and administered, but it can also cause serious adverse reactions. Severe hypersensitivity reactions and suppression of blood-cell production are among the important risks. It must therefore be used under specialist medical supervision.

4. Can Pacliwel be used for every type of cancer?

No. Paclitaxel is not appropriate for every cancer. Its use depends on the type and stage of cancer, previous treatments, individual patient factors, and applicable treatment guidelines. An oncologist determines whether paclitaxel is suitable for a particular patient.

5. What are the common Pacliwel side effects?

Paclitaxel treatment can be associated with hair loss, tiredness, nausea, changes in blood-cell counts, muscle or joint discomfort, and peripheral neuropathy. Side effects vary from person to person and may depend on the treatment regimen and combination medicines.

6. Can Pacliwel cause an allergic reaction?

Yes. Conventional paclitaxel injection can cause serious hypersensitivity reactions, including anaphylaxis. For this reason, patients receiving treatment are monitored carefully by qualified healthcare professionals, and appropriate precautions are taken according to the applicable product information.

7. Can Pacliwel affect blood counts?

Yes. Paclitaxel can suppress bone-marrow activity and reduce blood-cell counts, particularly neutrophils. This can increase susceptibility to infection and may require laboratory monitoring during treatment. The treating oncology team determines whether treatment should proceed based on clinical and laboratory findings.

8. Who should tell their doctor before receiving Pacliwel?

Patients should tell their healthcare team about allergies, previous chemotherapy reactions, liver or heart problems, nerve problems, pregnancy or breastfeeding, and all medicines or supplements they use. This information helps the oncology team assess potential risks and interactions.

9. Is Pacliwel suitable for self-treatment?

No. Pacliwel is a prescription cytotoxic chemotherapy medicine intended for administration by qualified healthcare professionals. It should never be self-administered or used based solely on information found online.

10. How should Pacliwel be stored?

Storage should follow the manufacturer’s approved product instructions. The medicine should remain under appropriate pharmaceutical control and be handled by authorized healthcare personnel. Cytotoxic medicines also require appropriate professional procedures for handling and disposal.

Disclaimer

This information about Pacliwel 30 mg/5 mL Injection (Paclitaxel) is provided for general educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Paclitaxel is a potent prescription chemotherapy medicine and should only be prescribed, prepared, and administered by appropriately qualified healthcare professionals. Do not self-medicate, alter a cancer treatment plan, or use information from this page to determine an individual treatment regimen.

Individual responses to paclitaxel vary. The treating oncologist should make all decisions regarding the suitability and clinical use of this medicine after considering the patient’s diagnosis, medical history, laboratory results, other medicines, and overall health.v